文献速递甲状腺疾病

RAS阳性Bethesda III和IV细胞学甲状腺结节的管理策略与结局

Outcomes of Patients with RAS-Positive Bethesda III and IV Cytology Thyroid Nodules.
PubMed 文献 · Thyroid · 2026-03-06

本研究回顾性分析了203例RAS阳性Bethesda III或IV甲状腺结节患者,其中62%接受手术、38%接受监测。手术组恶性率为34%,监测组中仅少数因生长或患者意愿转为手术,2年累积生长发生率为2%,提示对适当选择患者主动监测是安全可行的替代方案。

要点

  • RAS阳性结节中仅34%手术病理为恶性,单纯RAS突变不足以一律手术。
  • Bethesda III结节更多采用监测,恶性结节核异型性更常见。
  • 监测组2年累积生长发生率仅2%,交叉手术者均为低-中危恶性。

核心结论

  • 孤立性RAS突变本身可能不构成手术的绝对指征。
  • 对适当选择的RAS阳性结节患者,主动监测是可行且安全的替代方案。

研究设计与样本

  • 回顾性分析单中心前瞻性甲状腺结节数据库,纳入2020年7月30日至2024年9月30日间检测出孤立性RAS突变的Bethesda III或IV结节患者203例。

主要发现

  • 203例RAS阳性结节患者中,126例(62%)接受手术,77例(38%)接受监测,监测中位随访24个月(IQR 14-37)。
  • 手术组最终病理恶性43例(34%),其中8例(19%)为2025 ATA中-高危或高危,良性57例(45%),不确定或极低恶性潜能肿瘤26例(21%)。
  • 手术患者更年轻(45 vs 53岁,p=0.001),结节更大(最大径2.9 vs 2.5 cm,体积6.2 vs 3.8 cm³,p均<0.05)。
  • Bethesda III结节接受监测的比例高于手术(95% vs 81%,p=0.010);恶性结节中核异型性较良性更常见(70% vs 40%,p=0.007)。
  • 监测期间7例因患者意愿、结节生长或症状转为手术,其中2例为恶性(均为ATA低-中危);48例可评估监测患者中,采用50%增长阈值,3例(6%)出现生长,2年累积生长发生率为2%。

临床怎么用

  • 对孤立性RAS阳性的Bethesda III或IV结节,可考虑主动监测而非立即手术,尤其适用于Bethesda III、结节较小且年轻患者需个体化评估。
  • 监测期间应定期超声随访,关注结节生长及患者症状,必要时及时手术。

局限性

  • 本研究为单中心回顾性分析,随访时间有限,需更长期数据验证监测策略的安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Routine resection of all RAS-positive nodules may result in overtreatment for up to 50% of patients. We evaluated the management strategy and outcomes of RAS-positive nodules. METHODS: Following implementation of reflexive ThyroSPECTM molecular testing (MT) for all Bethesda III and IV thyroid nodules in July 2020, we identified patients with isolated RAS mutations between July 30, 2020, and September 30, 2024, using an institutional prospective thyroid nodule database. Patients were categorized by management strategy: surgery versus surveillance. Exclusion criteria included: absence of ultrasound (US) within 12 months prior to MT, incomplete post-MT management data, comutations with RAS, initial lobectomy before MT, concomitant fine-needle aspiration-proven papillary thyroid carcinomas or metastatic lymph nodes, and presence of contralateral high-risk nodules. This study represents a retrospective analysis of institutional registry data from a single health care region. RESULTS: Among 203 patients with RAS-positive nodules (175 Bethesda III, 28 Bethesda IV), 126 (62%) underwent surgery and 77 (38%) were under surveillance (median follow-up: 24 months, interquartile range 14-37). Final pathology in surgery group revealed malignancy in 43 (34%), with 8 (19%) 2025 American Thyroid Association (ATA) intermediate-high or high risk, 57 (45%) benign lesions, and 26 (21%) neoplasms of uncertain or very low malignant potential. Surgical patients were younger (45 vs. 53 years, p = 0.001) with larger nodules (maximum diameter 2.9 vs. 2.5 cm, volume 6.2 vs. 3.8 cm3, p < 0.05 for both). Bethesda III nodules were more frequently managed with surveillance than surgery (95% vs. 81%, p = 0.010). Nuclear atypia was more frequent in malignant versus benign resected nodules (70% vs. 40%, p = 0.007). Seven patients crossed over to surgery during surveillance due to patient preference, nodule growth, or symptoms; two had malignant pathology (both ATA low-intermediate risk). Nodule stability was evaluated in 48 surveillance patients with at least one post-MT US and minimum 1-year follow-up. Using a threshold of 50%, 3/48 (6%) exhibited growth, with a 2% cumulative incidence of growth at 2 years. CONCLUSIONS: Isolated RAS mutation alone may not uniformly mandate surgery. Active surveillance represents a viable and safe alternative to surgery in appropriately selected patients with RAS-positive nodules, though further long-term data are needed.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Wu J, Yeo C, Qi J, et al. Outcomes of Patients with RAS-Positive Bethesda III and IV Cytology Thyroid Nodules. Thyroid. 2026. PMID: 41789763. doi:10.1177/10507256261429119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。